Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) have earned an average recommendation of “Hold” from the seven analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $6.63.
A number of analysts recently issued reports on ZIOP shares. ValuEngine downgraded ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $5.50 target price on shares of ZIOPHARM Oncology in a report on Thursday, May 9th. BidaskClub cut ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a report on Wednesday, August 28th. Zacks Investment Research upgraded ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Raymond James began coverage on ZIOPHARM Oncology in a report on Thursday, August 22nd. They set an “outperform” rating and a $6.50 target price for the company.
Shares of NASDAQ:ZIOP traded down $0.25 during midday trading on Friday, reaching $4.49. 2,365,636 shares of the company’s stock were exchanged, compared to its average volume of 1,806,560. The firm’s 50 day simple moving average is $5.57 and its two-hundred day simple moving average is $4.64. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.33 and a quick ratio of 6.33. The stock has a market cap of $811.14 million, a price-to-earnings ratio of -9.35 and a beta of 2.73. ZIOPHARM Oncology has a fifty-two week low of $1.56 and a fifty-two week high of $7.25.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). During the same period in the previous year, the business earned ($0.12) earnings per share. Equities research analysts predict that ZIOPHARM Oncology will post -0.34 earnings per share for the current fiscal year.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in shares of ZIOPHARM Oncology by 24.3% in the 2nd quarter. BlackRock Inc. now owns 11,753,413 shares of the biotechnology company’s stock valued at $68,522,000 after buying an additional 2,294,498 shares during the period. Vanguard Group Inc. boosted its stake in shares of ZIOPHARM Oncology by 11.6% in the 2nd quarter. Vanguard Group Inc. now owns 11,254,728 shares of the biotechnology company’s stock valued at $65,615,000 after buying an additional 1,167,963 shares during the period. Northern Trust Corp lifted its stake in ZIOPHARM Oncology by 3.0% during the second quarter. Northern Trust Corp now owns 1,716,285 shares of the biotechnology company’s stock worth $10,007,000 after purchasing an additional 49,939 shares during the last quarter. Morgan Stanley lifted its stake in ZIOPHARM Oncology by 13.2% during the second quarter. Morgan Stanley now owns 1,385,120 shares of the biotechnology company’s stock worth $8,075,000 after purchasing an additional 161,833 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in ZIOPHARM Oncology by 7.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 898,615 shares of the biotechnology company’s stock worth $5,239,000 after purchasing an additional 63,762 shares during the last quarter. Institutional investors own 43.19% of the company’s stock.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Recommended Story: Producer Price Index (PPI)
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.